GlaxoSmithKline

GlaxoSmithKline

  • October 2020 •
  • 60 pages •
  • Report ID: 5780019 •
  • Format: PDF
PharmaVitae explores GlaxoSmithKline’s prescription pharmaceutical performance and outlook over 2019–29.

Snapshot
Overview – GlaxoSmithKline’s sales will grow steadily through to 2026 due to new launches.
Key themes – [1] Shingrix’s rapid growth will not be repeated over the coming years as GlaxoSmithKline is capacity-constrained until 2024 [2] Expansion into oncology with Zejula, belantamab mafodotin, dostarlimab, and bintrafusp alfa [3] HIV franchise in transition phase as market moves away from triple products to newer two-drug regimens like Dovato and cabotegravir + rilpivirine [4] Eventual IPO of the GlaxoSmithKline and Pfizer Consumer Healthcare Joint Venture will provide GSK with significant capital to potentially pursue MandA.

Model updates (3 August 2020)

Cabotegravir forecast added after recent results from Phase III studies in HIV prophylaxis
Infanrix/Pediarix forecast adjusted lower due to impact from COVID-19
Hepatitis vaccines forecast adjusted lower due to impact from COVID-19
Boostrix forecast adjusted lower due to impact from COVID-19.

Model updates (1 June 2020)

Juluca forecast adjusted lower.

Model updates (28 February 2020)

Shingrix forecast adjusted higher to account for more robust sales and significant capacity increase in 2024
Tivicay forecast adjusted lower due to competitive trends in the HIV market
Triumeq forecast adjusted lower due to competitive trends in the HIV market
Dovato forecast adjusted higher due to launch trend in the US
Juluca forecast adjusted higher due to launch trends globally
Fostemsavir forecast pushed out to align with filing timeframe.

Model updates (7 November 2019)

Triumeq forecast adjusted higher in the US
Juluca forecast adjusted lower internationally due to slower initial launch
Shingrix forecast adjusted higher globally.

Model updates (25 July 2019)

Advair forecast adjusted higher due to less impact from generics than anticipated
Anoro Ellipta forecast adjusted lower due to pricing pressure in the US
Incruse Ellipta forecast adjusted lower due to pricing pressure in the US
Breo Ellipta forecast adjusted lower due to pricing pressure in the US
Trelegy Ellipta forecast adjusted higher due to strong uptake
Tivicay forecast adjusted lower in the US
Flovent forecast adjusted higher in the US
Ventolin forecast adjusted higher in the US due to temporary benefit from authorized generic
Shingrix forecast adjusted higher in the US due to strong demand
Zejula forecast added
Dostarlimab forecast added
Bintrafusp alfa forecast added
Daprodustat forecast added
Belantamab mafodotin forecast added
Otilimab forecast added
Updated non-pharmaceutical revenue to account for pending GSK and PFE consumer healthcare joint venture, as well as intention to separate the joint venture via a demerger within three years of closing.